BDX vs GEHC future institutional interest and which is a better short and long term buy

**Becton, Dickinson (BDX) is poised for higher future institutional interest compared to GE HealthCare Technologies (GEHC)**, and is a better short-term investment, while GEHC is a stronger long-term buy. Here's why:

1. **Short-Term Institutional Interest**:
- BDX has recently seen an increase in institutional positions, with Procyon Advisors LLC boosting its position by 13.5% in Q3. This indicates growing interest from institutions in the near term.
- BDX's net change in short-term investments for the twelve months ending March 31, 2024, was -$0.815B, which is a significant decline year-over-year. This could be a sign that institutions are actively adjusting their positions in the short term.

2. **Long-Term Institutional Positioning**:
- GEHC, on the other hand, has shown more stable long-term institutional ownership, with institutions owning a substantial 75.16% of the company's shares. This suggests a strong and consistent institutional presence.
- GEHC's long-term investments have been stable, with no significant changes reported. This indicates a steady institutional commitment to the company's long-term strategy.

3. **Market Performance and Growth Prospects**:
- BDX has demonstrated strong organic revenue growth and cash flow, with reported revenue of $5.0 billion and adjusted diluted EPS of $3.50, which grew by 18.2%. This robust performance could attract more institutional interest in the short term.
- GEHC's financial performance has been positive, with a projected 6.3% growth for the next five years. This growth trajectory, while steady, may not be as immediately compelling as BDX's recent performance.
4. **Strategic Position and Innovation**:
- BDX is a leading medical technology company with a diverse product portfolio, which positions it well for continued growth. The company's focus on BD Excellence and execution has driven strong operating margins and cash flow.
- GEHC is a leading medical technology company with a focus on imaging and ultrasound equipment, which is expected to benefit from long-term healthcare trends. The company's commitment to innovation and recent acquisitions, such as the Intelligent Ultrasound's Clinical AI business, strengthen its position in the market.
5. **Valuation and Analyst Ratings**:
- BDX has received positive analyst ratings and price target increases, indicating strong confidence from analysts. This could attract more institutional interest, especially if the stock is undervalued.
- GEHC has also received positive ratings and price target increases, with a "buy" rating from various analysts. The company's wide economic moat and long-term growth potential are highlighted by analysts, which may appeal to long-term institutional investors.

In conclusion, while BDX shows stronger short-term momentum and potential for higher institutional interest due to its recent performance and positive analyst ratings, GEHC offers a more stable long-term investment opportunity with a higher and more consistent institutional ownership. Investors should consider their investment horizon and risk tolerance when choosing between these two stocks.